The signal
Four facts, all from the same window.
The market is tilting towards prevention. Eighty per cent of UK adults say they take a preventative approach to their beauty routine, and sixty per cent rank healthy ageing as a top priority. Dermocosmetics has posted double-digit annual growth across all regions between 2020 and 2024, with more than six hundred new dermatologically tested products launched online between September 2024 and August 2025.
The vocabulary is changing. Anti-ageing is giving way to skin longevity: cellular resilience, mitochondrial function, long-term vitality. A register borrowed from biology rather than from cosmetics.
Doubt is setting in. As the category expands, the industry faces growing scrutiny over whether products can genuinely substantiate these longevity claims. On skin barrier, the durability of the effect is becoming a differentiation criterion — and as of 2026 there is still no unified regulatory framework for substantiating such claims. ISO is progressively publishing biometrological measurement standards.
The regulator has arrived. The European Commission has restricted twelve cosmetic ingredients through Regulation (EU) 2026/909, applicable from 1 January 2027. Since 31 July 2026, products containing newly added fragrance allergens that do not comply with revised labelling requirements can no longer be placed on the EU market. On the commercial front, Italy's competition authority opened an investigation in March into Sephora and Benefit over the promotion of serums, masks and anti-ageing creams to children, some reportedly under the age of ten. In the United States, Sephora agreed with the Connecticut Attorney General to display clear warnings on the relevant sales pages.
What everyone is saying
That longevity is beauty's new growth territory. That the boundary between care and health is dissolving. That dermocosmetics is winning because it is credible. That artificial intelligence applied to skin diagnostics will personalise recommendation — a market estimated at around USD 0.86 billion in 2025, USD 1.02 billion in 2026, and projected at USD 2.45 billion by 2031.
All of that is accurate. And entirely insufficient to decide anything.
What it actually changes
The shift from anti-ageing to longevity is not a change of trend. It is a change of contract.
Anti-ageing was an aesthetic promise. Nobody expected a wrinkle cream to produce a clinical protocol; the promise was judged by eye, on oneself, within weeks. The consumer knew they were buying hope as much as active ingredient.
Skin longevity is a biological promise. When a brand talks about mitochondrial function, it is no longer speaking the language of desire but the language of demonstration. And a promise phrased in the language of science gets judged by the rules of science, whether the brand intended that or not.
This is where the trap closes. The industry adopted medical vocabulary before adopting medicine's burden of proof. And it did so in a regulatory vacuum: no harmonised framework exists today for substantiating a barrier or longevity claim. That vacuum has felt like freedom. It will close like a vice — ISO is advancing, national authorities are too, and the history of nutrition claims tells us exactly how this ends.
The second effect is blunter. The word “prevention” is commercially brilliant and ethically treacherous. If you must prevent, you must start early. And if starting early is virtuous, there is no natural lower limit. That is precisely the slope regulators are now attacking through the sale of anti-ageing products to children. This is not a merchandising lapse at one retailer: it is the logical consequence of a narrative the whole category built together.
The third effect is the one that decides the winners. In a category where everyone claims science, science stops being an argument and becomes a prerequisite. Differentiation shifts to an uncomfortable place: the ability to show your protocol. How many subjects, over what duration, measured how, against which comparator, published where. Few beauty brands are currently equipped to answer those five questions in public.
Those who build their own standard of proof now, before the norm arrives, will write the norm. Those who wait will be defined by it.
The calendar that matters
| Deadline | What changes | What it requires of brands |
|---|---|---|
| 31 July 2026 — in force | Products containing newly added fragrance allergens that do not meet revised labelling requirements can no longer be placed on the EU market | Review formulas and labelling, including legacy references |
| 1 January 2027 | Regulation (EU) 2026/909 applies new restrictions to twelve cosmetic ingredients | Anticipate reformulation and make portfolio trade-offs |
| Ongoing — ISO | Progressive publication of biometrological measurement standards, notably on skin barrier | Structure proof protocols before the standard imposes them |
| Ongoing — national authorities | Investigations into the promotion of anti-ageing products to minors | Write an internal rule on recommendation age, and hold to it |
The question to put to your committee next week
If a journalist asked us tomorrow to publish the protocol behind our flagship claim, would we be proud to show it?
Three possible answers. Yes, and we have never foregrounded it: that is a dormant marketing asset, and the work is a communication project. No, and we know it: the work is an R&D project, to be started before the next launch. We don't know: the most common answer, and the only genuinely worrying one.
A second question, equally useful: from what age do we accept our products being recommended, and have we written that rule down anywhere? If the answer does not exist internally, someone else will write it for you.